Blog
RSS FeedPosted by Michael Wonder on 02 Jan 2017
Radical plan for bigger Medicare rebates in the bush
3 January 2017 - Health fund members in regional and remote areas would be given larger Medicare payments or more ...
Posted by Michael Wonder on 02 Jan 2017
Bronchial carcinoma: additional use of crizotinib not seen
2 January 2017 - The dossier does not contain any suitable data for patients with ROS1 positive non-small-cell lung cancer. ...
Posted by Michael Wonder on 01 Jan 2017
New Zealand Pharmaceutical Schedule - 1 January 2017
1 January 2017 - The January 2017 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Dec 2016
Schedule of Pharmaceutical Benefits - 1 January 2017 update
1 January 2017 - The 1 January 2017 issue of the Schedule of Pharmaceutical Benefits sees a number of new ...
Posted by Michael Wonder on 31 Dec 2016
Breast cancer drug rejected for NHS use on cost-benefit grounds
29 December 2016 - Charities angered by guidance on Kadcyla, which costs £90,000 per year per patient and gives extra nine ...
Posted by Michael Wonder on 30 Dec 2016
AstraZeneca chief says NHS drug approval process hurts patients
29 December 2016 - Protracted negotiations deny access to life-saving treatments, says Pascal Soriot. ...
Posted by Michael Wonder on 23 Dec 2016
‘Wonder’ drug for sufferers given green light for NHS use
22 December 2016 - The decision means 6,890 people in England and Wales who suffer with the debilitating inflammatory disease ...
Posted by Michael Wonder on 21 Dec 2016
Summary of the agenda for the PBAC March 2017 meeting
22 December 2016 - The PBAC will consider 40 submissions (23 major & 17 minor) at its next scheduled meeting ...
Posted by Michael Wonder on 21 Dec 2016
Manual of resource items and their associated unit costs
21 December 2016 - The PBAC has endorsed version 5.0 of the Manual of resource items and their associated unit ...
Posted by Michael Wonder on 21 Dec 2016
Decision to list oral betaine for rare disorder
21 December 2016 - PHARMAC is pleased to announce the approval of an agreement with Emerge Health to list oral ...
Posted by Michael Wonder on 20 Dec 2016
Liberals fail to clinch 10-year health deal with provinces
19 December 2016 - Prime Minister Justin Trudeau’s campaign vow to improve federal-provincial relations has suffered a major blow as ...
Posted by Michael Wonder on 20 Dec 2016
Proposal to maintain full subsidy for gefitinib (Iressa) from 1 April 2017
20 December 2016 - PHARMAC is seeking feedback on a proposal to amend the contractual terms of funding for gefitinib ...
Posted by Michael Wonder on 19 Dec 2016
Aussie mums shunning private hospitals due to obscene obstetrics charges
16 December 2016 - Obstetrician charges of up to $10,000 and midwife led care in public hospitals are driving new ...
Posted by Michael Wonder on 19 Dec 2016
Vertex announces German reimbursement agreement for Orkambi (lumacaftor with ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation
19 December 2016 - Vertex Pharmaceuticals today announced it has reached a pricing and reimbursement agreement for Orkambi (lumacaftor with ...
Posted by Michael Wonder on 19 Dec 2016
Review of access to new medicines report
15 December 2016 - The Scottish Government has published Dr Brian Montgomery’s Review of Access to New Medicines, which assesses ...